FOXP3 and colitis: In MLNs cells, Foxp3+ Treg peaked in preventive group (6.16 ± 0.48) followed by S. obv group (5.17 ± 0.27) and therapeutic group (4.86 ± 0.28) but barely noticed in control group (3.55 ± 0.46) and DSS colitis group (2.26 ± 0.26).